Overview

A Study of MDI-1228_mesylate Ophthalmic Solution in Healthy Adults

Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
The main goal of this clinical trial is to evaluate the safety, tolerability and pharmacokinetics (PK) profiles* of MDI-1228_mesylate Ophthalmic Solution in healthy adult participants. Participants will receive either of the following treatment: - MDI-1228_mesylate Ophthalmic Solution, or - Placebo** Researchers will observe any changes in heath (if any) in participants receiving the study treatment to evaluate the safety and tolerability*** of the study drug. Researchers will also collect several blood samples from participants to study PK profiles of the drug. Note: - PK profiles: how the drug interacts with the body. **placebo: a harmless substance that contains no active agents. ***tolerability: how well you can tolerate the drug.
Phase:
Phase 1
Details
Lead Sponsor:
Shanghai Medinno Pharmaceutical Technology Co., Ltd.
Treatments:
Ophthalmic Solutions